Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Instructions to Pick the Right Dental Embed Trained professional: An Exhaustive Aide - 2The many ways that baking is winter therapy. With a delicious ending
- 3Day to day Temporary Positions That Compensate Fairly in the US
- 4What are the health benefits of whole milk for kids?
- 5Vote in favor of the Top Vegetable for Senior
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- Iran war triggering Easter staycation boom
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- Volkswagen Just Revealed a Massive Range-Extended SUV for China, and America Isn’t Getting It
- Earthquake in Indonesia kills at least 1 person and sets off small tsunami
- ‘Grit’ and relentless perseverance can take a toll on brain health − particularly for people facing social stresses like racism
- The 2026 'Super Bowl of Astronomy' starts today — here's what's happening
- More parents refusing vitamin K shots for newborns, study finds
- Fuel Price Spike Drives Surge in Used EV Sales in Europe
